NewAmsterdam Pharma

12/17/2025

Happy holidays and best wishes for a healthy and joyful New Year from all of us at NewAmsterdam Pharma! As we look ahead to 2026, we remain committed to advancing our lead investigational asset and exploring new ways to address the global impact of cardiovascular disease.

12/02/2025

Taking charge of your heart health is a team effort. Clinical recommendations help guide prevention, screening, and treatment—while your actions, like tracking risk factors and adopting healthy habits, make the difference.

Learn more about preventing heart disease from the American Heart Association: https://www.heart.org/en/healthy-living/healthy-lifestyle/how-to-help-prevent-heart-disease-at-any-age

11/24/2025

Lp(a) isn’t as well-known as LDL-C, but high levels can sharply increase the risk of heart attacks and strokes—even in people with normal LDL. This recent Washington Post st article explores the science behind Lp(a), its genetic roots, and why it’s gaining attention among researchers and clinicians.

https://wapo.st/48vKTaV

11/17/2025

Our focus always returns to the science and the patients we serve. Company meetings like the one we hosted last month reignite our energy, sharpen our clarity, and strengthen our connection to our shared mission and each other. Because when teams align around purpose, the impact goes far beyond the room.

11/14/2025

About 1 in 9 adults worldwide are living with diabetes, and the diagnosis doubles the risk for heart disease. People with type 2 diabetes have a similar risk of cardiovascular disease as those who already have it.

This , learn more about our research: https://www.newamsterdampharma.com/lipid-related-conditions/

11/09/2025

LDL-C isn’t the whole picture. Other factors like LDL particles, ApoB, Lp(a), non-HDL-C, and low HDL-C can contribute to residual ASCVD risk.

Learn about each of these factors: https://bit.ly/43iWOpI

10/28/2025

Even when taking statins, many ASCVD patients continue to face significant residual cardiovascular risk. Professor Stephen Nicholls highlights that while lowering LDL-C remains crucial, it’s not the only factor driving heart disease.

10/20/2025

We are excited to announce that our Alzheimer’s disease biomarker data from a prespecified substudy in our BROADWAY clinical trial has been peer-reviewed and published in the Journal of Prevention of Alzheimer’s Disease. These data were first presented at . 🔓 Read the open access article: https://bit.ly/47bwIGd

09/30/2025

Despite being on lipid-lowering therapies, many patients still have LDL-C levels above recommended targets. This LDL-C Awareness Day, take a moment for your health—talk to your doctor and see if it's time for a cholesterol check.

09/29/2025

Together, we won’t miss a beat.

This World Heart Day, we’re joining the global call to reduce the burden of cardiovascular disease, the world’s leading cause of death.

This year’s theme, “Don’t Miss a Beat,” is a powerful reminder to stay proactive about heart health. We’re advancing research in pursuit of a future where heart disease is no longer the #1 killer worldwide.

https://bit.ly/4nugjUo

09/24/2025

09/24/2025

Over 7 million Americans are living with Alzheimer’s disease. By 2050, that number is projected to reach nearly 13 million.

Cholesterol plays a critical role in brain health, and research suggests there could be a link between lipid metabolism in the brain and Alzheimer’s. Take a closer look at the science: https://bit.ly/4nQEvQI